THE mRNA VACCINE LIE

" In 2012, DARPA ( Defense Advanced Research Projects Agency ) began investing in gene-encoded vaccines.

"The army came up with the idea of messenger RNA vaccines, not Pfizer or Moderna - not operation warp speed of Trump,"

It is a lie that gene-encoded vaccines were developed in 6 months. Moderna had its first patent registered in 2013."

See video below.

DARPA is a division of the US military.

https://www.darpa.mil/

DARPA's website explains in detail the extent to which it controlled and monitored the Covid19 event and vaccination programs worldwide. It still does, by the way.

A MUST READ for those who wish to know all they do and the extent of its intervention and influence.

"Update 19.03.2021 :

Diagnosis and detection:

Diagnosis is a crucial aspect of pandemic prevention and response. DARPA research produces tests that enable earlier, more sensitive and widely distributed diagnosis of SARS-CoV-2 infected patients.

DARPA launched the Detect It with Gene Editing Technologies (DIGET) and Epigenetic CHaracterisation and Observation (ECHO) programs aimed at rapid discovery, validation and production of diagnostics that can detect any threat, anytime, anywhere.

DIGET, which recently awarded a contract to MRI Global, is advancing its goal of building a multiplexed detection device capable of screening up to a thousand pathogens simultaneously, along with a mobile device to detect up to 10 pathogens, including SARS-CoV-2. DARPA's ECHO program is developing diagnostic tests that measure the body's response to a viral infection rather than testing for the virus itself.

"ADEPT/P3.

As part of the ADEPT program in 2011, DARPA began investing in nucleic acid vaccines ( = mRNA ). The hypothesis was that instead of delivering antigens to the immune system, we could deliver genes that encode the antigen and allow the human body to produce the antigen from its own cells, triggering a protective immune response. In December 2020, former ADEPT implementer of Moderna's RNA vaccine received emergency use authorization (EUA) approval from the FDA for the prevention of COVID-19.

In FY2016, DARPA launched the Pandemic Prevention Platform (P3) program aimed at rapidly discovering, testing and producing antibody treatments to combat any emerging disease threat.

P3 has convincingly demonstrated how antibodies can be found and produced in less than 90 days (instead of years), with influenza, Zika and MERS as test cases. When the COVID-19 outbreak began in early 2020, P3's research was focused on the novel coronavirus.

In November 2020, AbCellera announced that bamlanivimab (LY-CoV555), a human monoclonal antibody (mAb) identified as part of the P3 program and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Centre (VRC), had received approval from the US Food and Drug Administration (FDA) for emergency use for the treatment of patients aged 12 years and older with mild to moderate COVID-19 to prevent hospitalization. AbCellera was able to obtain a blood sample through an intergovernmental panel in late February 2020 and identified more than 1,000 potential antibody candidates. The mAb is being developed in collaboration with Eli Lilly and Company.

On 21 January 2021, the company announced that bamlanivimab reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities by up to 80%. This was followed six days later by a second announcement that the mAb will be evaluated together with VIR-7831, an antibody developed by Vir Biotechnology, Inc, and GlaxoSmithKline, as a potential COVID-19 therapy in low-risk patients with mild to moderate COVID-19. In February 2021, bamlanivimab, administered with etesevimab, also received an EUA for the treatment of mild-to-moderate COVID-19 in patients aged 12 years and older at high risk of progression to severe COVID-19 and/or hospitalization.

A second antibody (AZD7442), discovered by Vanderbilt University Medical Center and licensed to AstraZeneca, is at an advanced stage of clinical trials to prevent COVID-19 disease, and researchers at Duke University are targeting clinical trials this year for their highly potent antibody targeting the receptor binding domain of SARS-CoV-2, which will be administered as an mRNA construct.

SIGMA+

DARPA's SIGMA+ program is developing gene network sensors for the detection of a variety of chemical, biological and explosive threats. Part of this research is aimed at tackling the COVID-19 pandemic.

As part of this program, Battelle Memorial Institute developed a unique signature for the SARS-CoV-2 virus using their Resource Effective Bio-identification System (REBS). The REBS platform is designed to monitor the atmosphere for the presence of biological warfare agents and other pathogens using a technique called Raman spectroscopy. Over the past year, work has been done to develop a signature for the virus that causes COVID-19. This signature is currently being evaluated in several trials using the REBS system and the newer REBS+ system that offers a range of performance improvements over the original REBS systems. For example, sampling time has been reduced from 30 minutes to just a few seconds.

The program is also evaluating the potential use of wearable technology to detect COVID-19 and other infectious diseases. The effort, led by RTI International and supported by Garmin® International, Inc, includes a number of studies on whether wearables can provide indications of infections based on an individual's immune response. One such study tracks the health of US Navy sailors living in tight quarters aboard ship via a new "app" to monitor high-quality wearables. The app allows continuous data collection in areas with limited or no access to Wi-Fi or mobile networks.

In addition to SIGMA+, the new SenSARS Disruption Opportunity aims to develop high-performance, air-breathing pathogen sensors for SARS-CoV-2 and beyond, targeted for use in offices, classrooms and buildings. New highly sensitive and highly specific signatures for SARS-CoV-2 will be researched, and these signatures will be used to produce prototypes of technology-level 4 sensors.

PANACEA

Previously FDA-approved drugs are a second option that can be immediately reused as effective treatments. DARPA developed several screening methods to quickly identify the best previously approved drugs, including rapid testing on human "organ-on-a-chip" systems, identification of drugs that target SARS-CoV-2 interactions with human cells rather than the virus itself, and the use of AI and machine learning methods to design and screen drugs.

The DARPA Panacea program has generated and published the first human:SARS-CoV-2 protein interactome map in the journal Nature, which describes how SARS-CoV-2 proteins interact with human cells. This map was developed by performers from the Quantitative Bioscience Institute (QBI) at UCSF and the Icahn School of Medicine at Mt Sinai (ISMMS) and is being used worldwide in the fight against COVID-19. The drug zotatifin, an inhibitor of protein synthesis identified by the Panacea implementers with their interaction map, will go to a phase 1 clinical trial in the first quarter of 2012 with investment support from the Defense Health Agency.

In January 2021, these implementers published their findings in Science, showing that Plitidepsin, a compound originally discovered in Mediterranean sea urchins and currently used as a therapeutic for the treatment of multiple myeloma, is 27.5 times more potent against SARS-CoV-2 than remdesivir in vitro. Remdesivir received an FDA emergency use authorization for the treatment of COVID-19 in 2020.

INTERCEPT

Researchers at Los Alamos National Laboratory (LANL), supported by DARPA's INTERCEPT program, are modelling the spread of COVID-19 among humans and among the population by combining clinical data and mathematical modelling to gain a quantitative understanding of the SARS-CoV-2 infection process within infected individuals and derive principles for therapeutic treatments to limit the spread, reduce the severity of the disease and minimize the risk of resistance. In a manuscript published in Clinical Pharmacology & Therapeutics, the researchers review the current literature on the use of within-host models to understand the dynamics of SARS-CoV-2 infection and their relationship with infectivity, immune responses and disease severity. This work provides an up-to-date synthesis of what is known about quantitative SARS-CoV-2 viral dynamics and their implications for both non-pharmaceutical and pharmaceutical interventions, such as therapeutics and vaccines.

Another INTERCEPT participant, Autonomous Therapeutics, Inc (ATI), is developing therapeutics that provide protection against any coronavirus - from newly mutated strains of COVID-19 to the next (unpredictable) threat. Called Therapeutic Interfering Particles (TIPs), these broad-spectrum antivirals can be developed and stockpiled before the next threat arises or is even known. The development of TIPs is supported by INTERCEPT, with additional support for clinical transition from leading private investors and a partnership with BARDA and Johnson and Johnson under the name Blue Knight.

ATI is also developing non-invasive platform technologies to enable home distribution of next-generation gene-coded antivirals. The technology would remove a major obstacle to the distribution of leading vaccines and monoclonal antibodies, which need to be administered intramusculary (IM) or intravenously (IV) in centralieed clinical settings.

PREPARE

On 3 February 2021, a PREPARE implementation team from Georgia Tech and colleagues published a paper in Nature highlighting a novel mRNA treatment as a potential therapeutic against both influenza A virus and SARS-COV-2 using Cas13a constructs ( = gene editing ) they developed as part of the program.

Manufacture process:

The COVID-19 pandemic revealed vulnerabilities in the US pharmaceutical supply chain. Work under DARPA's Make-It program is advancing the development and commercialization of technology that directly addresses these vulnerabilities to enable an end-to-end, deployable and scalable capability for manufacturing drugs from readily available raw materials that can be sourced in the US.

AMD implementers are working with the Walter Reed Army Institute of Research (WRAIR) to apply artificial intelligence (AI) to accelerate drug discovery against SARS-CoV-2. Under this program, the NIH National Center for Advancing Translational Sciences (NCATS) and WRAIR are providing medicinal chemistry expertise to MIT and SRI, as well as conducting in vitro tests on the AI predictions to validate and inform the models.

Researchers at MIT are focusing on developing new AI algorithms that specifically address the data scarcity problem inherent in studying a new virus, and want to apply such techniques to identify synergistic combination therapies in the future. They recently published blog posts on the results of their model trained to predict antiviral activity against COVID-19, and on efforts to develop machine-learning tools to help identify molecules with therapeutic effects against the disease.

AMD collaborators at SRI International are developing AI tools that integrate the expert knowledge of chemists, alongside that learned from data, to discover analogues of existing therapeutics with potency against SARS-CoV-2. They have also recently published data on using machine learning models to identify inhibitors of the virus.

Make-It

Under Make-It, the production of active pharmaceutical ingredients (APIs) was further automated and expanded to enable the flexible and scalable production of a wide range of APIs. Current efforts are focused on meeting regulatory approval requirements and expanding capacity to enable production of critical drugs and precursors needed to treat COVID-19 patients in critical care.

Make-It executives are building a range of flexible manufacturing capabilities for scalable, resilient production of key drugs:

On Demand Pharmaceuticals (ODP) focuses on the production of fine chemical reagents and active pharmaceutical ingredients (APIs), and their technology is based on small chemical manufacturing devices developed in DARPA's Battlefield Medicine and Make-It programmes. Their efforts are jointly funded by DARPA and HHS under the CARES Act, and the company received a visit on 3 December from FDA Commissioner, Dr Stephen Hahn, and from DARPA's Deputy Director, Dr Peter Highnam.

SRI International is developing an approach that allows pharmaceutical production to scale up from workbench to production scale in one step.

Virginia Commonwealth University is building tools to analyze and optimize chemical production in the US so that in times of need, existing on-shore process streams can be quickly repurposed for critical APIs.

More info via this link.

https://www.darpa.mil/work-with-us/covid-19

In the text, click on the words and programs in blue.

The US controls the EU. The EU commission controls all member states. Under the Covid pandemic, DARPA dictated all the rules, including testing and vaccination with a gene-encoded vaccine.

Gene editing alters the genetic material of humans. All those who have claimed that this was a " conspiracy theory " have lied through teeth.